Active Clinical Trials

April 15, 2022

Trial Spotlight: Nadine Tung on the EA1181/CompassHER2 pCR Trial for HER2-Positive Breast Cancer

This study aims to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with pathologic complete response (pCR) after 12 weeks of pre-operative treatment
February 24, 2022

Now Enrolling: EA2205 for a Rare Form of Liver Cancer

ECOG-ACRIN is leading the first randomized trial evaluating treatment strategies for patients with combined hepatocellular carcinoma-cholangiocarcinoma
February 24, 2022

Trial Spotlight: Nataliya Uboha on the EA2183 Trial for Esophageal and Gastric Adenocarcinoma

This randomized phase III trial explores the addition of radiotherapy to the usual treatment (chemotherapy) in patients with esophagus and stomach cancer with limited spread
January 26, 2022

Now Enrolling: EA3202 for Head and Neck Squamous Cell Carcinoma

This phase II/III study is exploring new treatment approaches for patients with recurrent and metastatic head and neck squamous cell carcinoma
January 26, 2022

Trial Spotlight: Jarushka Naidoo on the EAQ172 Trial for Steroid-Refractory Pneumonitis

This randomized phase II trial aims to establish which agent, infliximab versus intravenous immunoglobulin, may lead to greatest benefit as pneumonitis treatment for patients receiving PD-1/PD-L1 therapy
December 22, 2021

Now Enrolling: EAQ201 to Assess COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST Participation

This observational study aims to assess the effects of the pandemic as a barrier to enrollment in the TMIST breast cancer screening trial
December 22, 2021

Trial Spotlight: Helena Yu on the EA5182 Trial for Metastatic, EGFR-Mutant Non-Small Cell Lung Cancer

This trial aims to help define the optimal first-line treatment for patients with advanced, EGFR-mutant NSCLC and elucidate mechanisms of resistance to therapy
November 16, 2021

Now Enrolling: EAQ202 to Improve Adolescent and Young Adult Self-Reported Data

This pilot study is determining the feasibility and acceptability for adult and young adult participants patients between the ages of 18 and 39 in ECOG-ACRIN treatment trials to use the National Institutes of Health’s Patient-Reported Outcomes Measurement Information System (PROMIS®)
November 16, 2021

Trial Spotlight: Ravi Amaravadi on the EA6191/BAMM2 Trial for Melanoma

This phase II randomized controlled trial is evaluating the effect of adding hydroxychloroquine to treatment with dabrafenib and trametinib in patients with advanced BRAF mutant melanoma
October 19, 2021

Trial Spotlight: Elyse Park on EAQ171CD – the Smoke-Free Support Study 2.0

This phase II randomized controlled trial is comparing the effectiveness of two different approaches to help recently diagnosed patients with cancer become smoke-free
September 30, 2021

Now Enrolling: Phase II of EA9152 for Acute Lymphoblastic Leukemia

This phase Ib/II study is testing the effects and safety of venetoclax in combination with liposomal vincristinein patients with B-ALL or T-ALL
September 30, 2021

NCI-MATCH Eliminates the Need for a Formal Referral Letter from the Laboratories

Removing one of several steps will help speed the process for identifying patients who may be eligible to enroll for treatment in NCI-MATCH